Augmedix Statistics
Total Valuation
Augmedix has a market cap or net worth of $138.91 million. The enterprise value is $118.41 million.
| Market Cap | 138.91M |
| Enterprise Value | 118.41M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Augmedix has 48.74 million shares outstanding. The number of shares has increased by 17.45% in one year.
| Shares Outstanding | 48.74M |
| Shares Change (YoY) | +17.45% |
| Shares Change (QoQ) | +7.81% |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 76.67% |
| Float | 28.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.10 |
| Forward PS | 2.23 |
| PB Ratio | 5.96 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.41, with a Debt / Equity ratio of 1.11.
| Current Ratio | 2.41 |
| Quick Ratio | 2.33 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.44 |
Financial Efficiency
Return on equity (ROE) is -308.50% and return on invested capital (ROIC) is -38.19%.
| Return on Equity (ROE) | -308.50% |
| Return on Assets (ROA) | -41.60% |
| Return on Capital (ROIC) | -38.19% |
| Revenue Per Employee | $31,367 |
| Profits Per Employee | -$13,406 |
| Employee Count | 1,430 |
| Asset Turnover | 0.97 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Augmedix has paid $145,000 in taxes.
| Income Tax | 145,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.00% in the last 52 weeks. The beta is -0.13, so Augmedix's price volatility has been lower than the market average.
| Beta (1Y) | -0.13 |
| 52-Week Price Change | -5.00% |
| 50-Day Moving Average | 3.93 |
| 200-Day Moving Average | 4.70 |
| Relative Strength Index (RSI) | 24.94 |
| Average Volume (30 Days) | 372,258 |
Short Selling Information
The latest short interest is 831,537, so 1.71% of the outstanding shares have been sold short.
| Short Interest | 831,537 |
| Short Previous Month | 747,989 |
| Short % of Shares Out | 1.71% |
| Short % of Float | 2.88% |
| Short Ratio (days to cover) | 2.10 |
Income Statement
In the last 12 months, Augmedix had revenue of $44.86 million and -$19.17 million in losses. Loss per share was -$0.44.
| Revenue | 44.86M |
| Gross Profit | 21.53M |
| Operating Income | -18.78M |
| Pretax Income | -19.03M |
| Net Income | -19.17M |
| EBITDA | -14.63M |
| EBIT | -16.77M |
| Loss Per Share | -$0.44 |
Balance Sheet
The company has $46.34 million in cash and $25.85 million in debt, giving a net cash position of $20.50 million or $0.42 per share.
| Cash & Cash Equivalents | 46.34M |
| Total Debt | 25.85M |
| Net Cash | 20.50M |
| Net Cash Per Share | $0.42 |
| Equity / Book Value | 23.32M |
| Book Value Per Share | 0.48 |
| Working Capital | 33.21M |
Cash Flow
In the last 12 months, operating cash flow was -$15.44 million and capital expenditures -$3.11 million, giving a free cash flow of -$18.55 million.
| Operating Cash Flow | -15.44M |
| Capital Expenditures | -3.11M |
| Free Cash Flow | -18.55M |
| FCF Per Share | -$0.42 |
Margins
Gross margin is 47.99%, with operating and profit margins of -41.87% and -42.74%.
| Gross Margin | 47.99% |
| Operating Margin | -41.87% |
| Pretax Margin | -42.42% |
| Profit Margin | -42.74% |
| EBITDA Margin | -32.62% |
| EBIT Margin | -37.39% |
| FCF Margin | -41.35% |
Dividends & Yields
Augmedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.45% |
| Shareholder Yield | -17.45% |
| Earnings Yield | -13.80% |
| FCF Yield | -13.35% |
Analyst Forecast
The average price target for Augmedix is $5.38, which is 88.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.38 |
| Price Target Difference | 88.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Augmedix has an Altman Z-Score of -0.68 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.68 |
| Piotroski F-Score | 4 |